4'-Hydroxynorendoxifen
 | |
| Clinical data | |
|---|---|
| Synonyms | N,N-Didesmethyl-4,4'-dihydroxytamoxifen |
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C24H25NO3 |
| Molar mass | 375.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4'-Hydroxynorendoxifen is a synthetic, nonsteroidal antiestrogen of the triphenylethylene group.[1][2] It is a dual selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), and was derived from tamoxifen, a SERM, and norendoxifen, a metabolite of tamoxifen that has been found to act as an AI.[1][2] The drug has been suggested for potential development as a treatment for estrogen receptor (ER)-positive breast cancer.[1][2] It was synthesized in 2015.[1]
References
- 1 2 3 4 Lv W, Liu J, Skaar TC, Flockhart DA, Cushman M (2015). "Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities". J. Med. Chem. 58 (6): 2623–48. doi:10.1021/jm501218e. PMC 4687028. PMID 25751283.
- 1 2 3 Nagini, S. (2017). Breast cancer: current molecular therapeutic targets and new players. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 17(2), 152–163.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.